In previously published articles, POLE2 has been identified as part of a set of molecular biomarkers or target genes in metastatic advanced bladder cancer patients as well it is one of the genes in a model to predict survival in mantle-cell lymphoma [19, 20]. Here, POLE2 is linked to urinary bladder carcinoma.